Free Trial

Haleon PLC Sponsored ADR (NYSE:HLN) Given Average Recommendation of "Moderate Buy" by Brokerages

Haleon logo with Medical background

Key Points

  • Haleon PLC has a consensus rating of "Moderate Buy" from ten brokerages, with an average one-year price target of $12.33.
  • The company recently increased its semi-annual dividend to $0.0555, marking a yield of 190.0% and an increase from the previous dividend of $0.05.
  • Multiple institutional investors have recently adjusted their stakes in Haleon, with hedge funds owning 6.67% of the company's stock.
  • MarketBeat previews the top five stocks to own by November 1st.

Haleon PLC Sponsored ADR (NYSE:HLN - Get Free Report) has been given a consensus rating of "Moderate Buy" by the ten brokerages that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $12.3250.

Several brokerages recently weighed in on HLN. Weiss Ratings reaffirmed a "hold (c)" rating on shares of Haleon in a report on Wednesday, October 8th. The Goldman Sachs Group raised Haleon from a "neutral" rating to a "buy" rating in a report on Wednesday, September 10th. Barclays downgraded Haleon from an "overweight" rating to an "equal weight" rating in a report on Tuesday, September 16th. Finally, Wall Street Zen downgraded Haleon from a "buy" rating to a "hold" rating in a report on Saturday, July 12th.

View Our Latest Research Report on Haleon

Haleon Price Performance

Shares of NYSE HLN opened at $8.99 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 0.87 and a quick ratio of 0.63. The stock has a fifty day moving average price of $9.42 and a 200 day moving average price of $10.02. Haleon has a 1-year low of $8.71 and a 1-year high of $11.42. The company has a market cap of $40.01 billion, a PE ratio of 23.04, a P/E/G ratio of 2.64 and a beta of 0.20.

Haleon Increases Dividend

The firm also recently announced a semi-annual dividend, which was paid on Thursday, September 18th. Shareholders of record on Friday, August 15th were issued a $0.0555 dividend. This represents a yield of 190.0%. This is an increase from Haleon's previous semi-annual dividend of $0.05. The ex-dividend date of this dividend was Friday, August 15th. Haleon's dividend payout ratio is 28.21%.

Institutional Investors Weigh In On Haleon

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Lester Murray Antman dba SimplyRich lifted its holdings in Haleon by 4.4% in the third quarter. Lester Murray Antman dba SimplyRich now owns 66,049 shares of the company's stock valued at $592,000 after acquiring an additional 2,783 shares during the period. Trust Point Inc. acquired a new position in shares of Haleon during the 3rd quarter worth $203,000. Baker Tilly Wealth Management LLC raised its stake in shares of Haleon by 10.3% during the 3rd quarter. Baker Tilly Wealth Management LLC now owns 72,712 shares of the company's stock worth $652,000 after buying an additional 6,770 shares during the last quarter. Country Club Bank raised its stake in shares of Haleon by 26.8% during the 3rd quarter. Country Club Bank now owns 19,621 shares of the company's stock worth $173,000 after buying an additional 4,152 shares during the last quarter. Finally, Sanders Morris Harris LLC acquired a new position in shares of Haleon during the 3rd quarter worth $150,000. Institutional investors and hedge funds own 6.67% of the company's stock.

Haleon Company Profile

(Get Free Report)

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

Read More

Analyst Recommendations for Haleon (NYSE:HLN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Haleon Right Now?

Before you consider Haleon, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haleon wasn't on the list.

While Haleon currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.